Stay updated with breaking news from Late Clinical Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Approval by European Commission would expand Reblozyl’s indication to include first-line treatment of anemia in adults with MDS in Europe In the pivotal Phase 3 COMMANDS study, Reblozyl nearly...
Luspatercept has been recommended for approval by the EMA for patients with transfusion-dependent anemia and lower-risk myelodysplastic syndromes.
Liso-cel sBLAs for indications in relapsed/refractory FL and MCL after exposure to a BTK inhibitor have received priority review from the FDA.
PRINCETON, N.J.--(BUSINESS WIRE)--Jan 30, 2024--
PALM BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports show that the Multiple myeloma Diagnostic market will...